RenovoRx Reports First Quarter 2022 Financial Results
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022.
- RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022.
- RenovoRx is fighting cancer through our innovative localized treatment of difficult-to-treat tumors via our proprietary RenovoTAMP (RenovoRx Trans-Arterial Micro-Perfusion) therapy platform, said Shaun Bagai, CEO of RenovoRx.
- Financial Highlights for the Quarter Ended March 31, 2022
Cash and cash equivalents as of March 31, 2022, were $13.1 million. - Research and development expenses were $1.3 million for the quarter ended March 31, 2022, compared to $0.6 million for the quarter ended March 31, 2021.